Recent Advances in the Treatment of Preterm Newborn Infants with Patent Ductus Arteriosus

Clin Perinatol. 2016 Mar;43(1):113-29. doi: 10.1016/j.clp.2015.11.008.


A patent ductus arteriosus (PDA) is associated with several adverse clinical conditions. Several strategies for PDA treatment exist, although data regarding the benefits of PDA treatment on outcomes are sparse. Moreover, the optimal treatment strategy for preterm neonates with PDA remains subject to debate. It is still unknown whether and when PDA treatment should be initiated and which approach (conservative, pharmacologic, or surgical) is best for individual patients (tailored therapies). This article reviews the current strategies for PDA treatment with a special focus on recent developments such as oral ibuprofen, high-dose regimens, and the use of paracetamol (oral, intravenous).

Keywords: Ibuprofen; Indomethacin; Paracetamol; Patent ductus arteriosus; Preterm infant; Very low birth weight.

Publication types

  • Review

MeSH terms

  • Acetaminophen / therapeutic use
  • Administration, Intravenous
  • Administration, Oral
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Cardiac Catheterization / methods*
  • Ductus Arteriosus, Patent / therapy*
  • Humans
  • Ibuprofen / therapeutic use
  • Indomethacin / therapeutic use
  • Infant, Newborn
  • Infant, Premature
  • Infant, Very Low Birth Weight
  • Intensive Care Units, Neonatal
  • Ligation


  • Anti-Inflammatory Agents, Non-Steroidal
  • Acetaminophen
  • Ibuprofen
  • Indomethacin